Tag: Immunotherapy

A new cost-effectiveness analysis finds nivolumab plus ipilimumab may offer greater quality-adjusted life years at lower cost than pembrolizumab as ...

A comprehensive bibliometric analysis of 979 publications reveals how single-cell RNA sequencing has evolved from cell cataloging to a dynamic, ...

First clinical data from the Phase 1b/2 BNT324-01 trial show that the investigational combination of pumitamig and elfetabart drozuntecan achieved ...

The 2025 Chinese guidelines consolidate two decades of evidence into an updated roadmap for diagnosing, preventing and treating colorectal cancer ...

A Japanese study found that immune-related adverse events during checkpoint inhibitor therapy for advanced gastric cancer were independently linked to ...

Five-year results from the KEYNOTE-826 trial confirm that adding pembrolizumab to first-line chemotherapy delivers durable survival benefit for patients with ...

The randomized Phase 2 DeLLphi-309 study found that extended-interval tarlatamab dosing every three or four weeks produced efficacy, safety and ...

A new review maps the laboratory models—from organoids to humanised mice to computational pipelines—that could finally bring personalised treatment to ...

New research shows that CD55 acts as a self-sufficient ignition switch for natural killer cell attack on tumors, and that ...

Six emerging cancer researchers outline in a Nature Reviews Cancer anniversary viewpoint the technologies and paradigms that will shape oncology ...